Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)

Fulminant Hepatic Failure Clinical Trial

— ELAD  

Official title:

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00832728
• Other study ID #: VTI-202
• Status: Withdrawn
• Phase: Phase 2
• First received: January 29, 2009
• Last updated: July 24, 2012
• Start date: March 2009
• Est. completion date: September 2011

Study information

• Verified date: July 2012
• Source: Vital Therapies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label, randomized, concurrent control study of subjects with FHF. Subjects meeting the eligibility requirements of the study will be randomly assigned in a 2:1 ratio to receive either standard medical therapy for FHF plus the ELAD® system, or standard medical therapy alone, with the latter defined as conventional therapy for FHF determined to be clinically appropriate by the treating physician.

Description:

Therapy will generally include treatment of hepatic encephalopathy using lactulose with or without oral antibiotics, antibiotics as indicated to treat infection, volume resuscitation and vasopressors as indicated to treat hypotension. In addition general medical treatment such as glucose control and renal replacement therapy will be used as necessary. Subjects with a clinical diagnosis of hepato-renal syndrome may be treated with midodrine and octreotide or terlipressin, if considered appropriate therapy.

Immediately prior to treatment initiation, subject eligibility will be confirmed. Treatment with ELAD® will continue for a minimum of 3 days and up to a maximum of 30 days, until, in the Investigator's opinion, clinical status improves relative to entry; until the subject undergoes OLT; or until the continued use of ELAD® is contraindicated, as described in Section 5.5. Subjects will be followed until discontinuation or 30 days has elapsed since study enrollment (control) or 30 days has elapsed since cessation of ELAD® therapy (ELAD® group), whichever comes first.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 10 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Weight =15 kilograms;

2. Age =10 =65 years;

3. Diagnosis of FHF;

4. Patients must have been treated with a standard regimen of N-acetyl cysteine (NAC) involving a loading dose of 150mg/kg/hr over 1 hour followed by 12.5 mg/kg/hour x 4 hours then continuous infusion of 6.25 mg/kg for the remaining 67 hrs.

5. Subject or designated representative must be willing to sign an Informed Consent Form specific to this study and comply with study requirements AND EITHER

6. Known acetaminophen ingestion or diagnostic serum level, and at least one of the following:

a. prothrombin time (PT) >30 seconds (International Normalized Ratio (INR) >6.5, OR; b. Encephalopathy Grade II, III or IV and at least one of the following: i. Arterial pH <7.30 at =2 hours after initial diagnosis, OR; ii. renal failure documented by urine output less than 2 mL/kg/hr over 12 hours, OR; iii. creatinine >2.5 mg/dL; OR

7. Patients with Non-Acetaminophen-Induced FHF:

a. Stage II, III or IV encephalopathy, and the presence of at least two of the following five criteria: i. Non-A/Non-B hepatitis or drug (non-acetaminophen) induced FHF; ii. Serum bilirubin >17 mg/dL; iii. Patient =10 or <40 years old; iv. Prothrombin time >25 seconds (INR > 3.5), AND/OR; v. Jaundice to encephalopathy time =7 days; OR

8. Liver transplantation within 10 days of the screening procedures, but meeting inclusion criteria due to primary graft non-function, and not receiving ELAD® therapy prior to the first graft

Exclusion Criteria:

1. Cerebral Perfusion Pressure as measured by an intracranial pressure (ICP) monitor. (NOTE: In those cases where ICP monitor placement cannot be performed prior to study enrollment, this exclusion criterion will not apply):

1. Patients > 18 yrs of age with Cerebral Perfusion Pressures (CPP) =40 mm Hg for one hour or longer.

2. Patients =18 yrs with CPP =35 mm Hg for one hour or longer.

2. Chronic liver disease;

3. Concomitant disease including chronic congestive heart failure, vascular disease, emphysema, AIDS, cancer, acute fatty-liver disease, hepatitis due to herpes virus, Wilson's disease, or Budd-Chiari syndrome;

4. Portal hypertension (e.g., variceal bleed, caput Medusae, and clinically obvious ascites);

5. Liver dysfunction due to trauma;

6. Hemorrhage or irreversible brain death ( i.e. blood flow studies positive for herniation and/or pupillary reflex absent);

7. Platelet count <50,000/mm3 or reducing to <80,000/mm3 over a 72 hr. period. (NOTE:

Patient may be included at the physician's discretion if platelet count exceeds 50,000mm3 at time of initiation of therapy and can be managed through the administration of blood products);

8. Mean Arterial Pressures (MAP) =50 mm Hg for one hour or longer as measured by an indwelling arterial line, OR; patients =18 years old and whose MAP is =40 mm Hg for one hour or longer;

9. Vasopressor support exceeding 1.0 µg/kg/min of an alpha-adrenergic agent for one hour or longer;

10. Clinical or radiographic evidence of stroke or intracerebral bleeding;

11. Seizures uncontrolled by medication;

12. Acute myocardial infarction based on clinical and/or electrocardiographic evidence;

13. Lung disease defined by a PaO2 = 60mm Hg or an FiO2 =0.6, not corrected by medical management (including CVVH if indicated);

14. Pregnancy as determined by ßhCG results;

15. =2 weeks postpartum;

16. Participation in another investigational study within 30 days of enrollment;

17. Prior ELAD® therapy.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fulminant Hepatic Failure
• Liver Failure
• Liver Failure, Acute

Intervention

Other:
• Standard of Care
Standard hospital protocol for the treatment of acute liver failure

Device:
• ELAD®
ELAD therapy

Locations

Country	Name	City	State
United States	University of Virginia	Charlottesville	Virginia
United States	Loyola University Medical Center	Chicago	Illinois
United States	University of Chicago Medical Center	Chicago	Illinois
United States	Indiana University	Indianapolis	Indiana
United States	Scripps Green Hospital	La Jolla	California
United States	Cedars Sinai Medical Center	Los Angeles	California
United States	New York University Medical Center	New York	New York
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Temple University Hospital	Philadelphia	Pennsylvania
United States	University of Rochester, Strong Memorial	Rochester	New York
United States	California Pacific Medical Center	San Francisco	California
United States	Louisiana State University Health Sciences Center-Shreveport	Shreveport	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Vital Therapies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effect of ELAD® therapy: 1) as a bridge-to-transplant/recovery and 2) on 30-day transplant-free survival in subjects with FHF		30 day	No
Primary	To assess its safety when used for a minimum of 3 days or up to a maximum of 30 days of treatment		30 day	No